Products, Major Customers and Concentrations of Credit Risks

Our primary product groups are infusion therapy, critical care, oncology and other. The breakdown by market segment for the years ended December 31, 2013, 2012 and 2011 are as follows:



	2013		2012		2011
Infusion therapy	$	211,249	$	215,319	$	198,888
Critical Care	51,484		55,519		61,400
Oncology	37,505		30,311		24,413
Other	13,478		15,751		17,494
	$	313,716	$	316,900	$	302,195

We sell products worldwide, on credit terms on an unsecured basis, to medical product manufacturers, independent medical supply distributors, and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. For the years ended December 31, 2013, 2012 and 2011, we had worldwide sales to one manufacturer, Hospira, of 39%, 42% and 42%, respectively, of consolidated revenue. As of December 31, 2013, and 2012, we had accounts receivable from Hospira of 32% and 35%, respectively, of consolidated accounts receivable.

Domestic sales accounted for 71%, 75% and 74% of total revenue in 2013, 2012 and 2011, respectively. International sales, which are determined by the destination of the product shipment, accounted for 29%, 25% and 26% of total revenue in 2013, 2012 and 2011, respectively.

The table below presents our long-lived assets by country:



	As of December 31,
	2013		2012
Mexico	$	49,454	47,461
Slovakia	18,422		16,224
Italy	5,428		5,027
Germany	547		212
Total foreign	$	73,851	$	68,924
United States	139,150		129,849
Worldwide total	$	213,001	$	198,773